Articles

RAHWAY, N.J., Nov. 16, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human…

(WENY) — November marks national stomach cancer awareness month with new cases affecting roughly 15,000 men and 10,000 women in 2023. The most common type of stomach cancer is Adenocarcinoma however there are other types of ways to identify the disease. Read more>

The PD-L1 IHC 22C3 pharmDx companion diagnostic tool is now FDA-approved to aid in the identification of patients with gastric or GEJ adenocarcinoma for whom pembrolizumab is a suitable treatment, according to Agilent Technologies, the device’s manufacturer.1 Read more>

RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or…

MADRID — Pembrolizumab with chemotherapy before and after surgery increased pathologic complete response among patients with locally advanced gastric or gastroesophageal junction cancer, according to findings presented at ESMO Congress. However, the approach did not confer a statistically significant benefit in EFS or OS, results of the randomized phase 3 KEYNOTE-585 study showed. Read more>

Patients with advanced/metastatic non–human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC) and treated with Opdivo (nivolumab) and chemotherapy maintained their health-related quality of life (HRQoL) “with a reduced risk of definitive deterioration in disease-related and overall health status and without increased treatment-related symptom burden” when compared with patients…

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, and for the treatment of…

The AACR-Debbie’s Dream Foundation Career Development Award for Gastric Cancer Research represents a joint effort to encourage and support junior faculty to conduct gastric cancer research and to establish a successful career path in this field. Learn More>

Gastrectomy causes vitamin B-12 deficiency since vitamin B-12 requires gastric acid and intrinsic factor for its absorption. Vitamin B-12 deficiency is considered to develop years after gastrectomy because of large hepatic storage. However, most gastric cancer develops after long-standing atrophic gastritis with vitamin B-12 malabsorption. We have investigated vita-min B-12 status in 22 patients before…

Older adults with gastrointestinal cancers who had inadequate emotional support were more likely to have poor physical and mental health-related quality of life, in addition to depression, compared to those with adequate emotional support, according to findings from a recent study. Of note, the patients with and without adequate emotional support did not have major…